TransCode Therapeutics’ (RNAZ) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of TransCode Therapeutics (NASDAQ:RNAZ) in a research note published on Friday, Benzinga reports. They currently have a $3.00 target price on the stock.

TransCode Therapeutics Stock Down 3.1 %

Shares of TransCode Therapeutics stock opened at $0.26 on Friday. The company has a 50-day moving average of $0.45 and a two-hundred day moving average of $0.74. TransCode Therapeutics has a 12-month low of $0.22 and a 12-month high of $128.00.

TransCode Therapeutics (NASDAQ:RNAZ) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.16). As a group, equities research analysts forecast that TransCode Therapeutics will post -2.05 earnings per share for the current year.

Hedge Funds Weigh In On TransCode Therapeutics

A hedge fund recently bought a new stake in TransCode Therapeutics stock. Virtu Financial LLC purchased a new position in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 55,329 shares of the company’s stock, valued at approximately $37,000. Virtu Financial LLC owned about 0.84% of TransCode Therapeutics as of its most recent SEC filing.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.